Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the Treatment of Cancer: A Review
Aziz Unnisa, Ananda Kumar Chettupalli, Talib Hussain, et al.
Anti-Cancer Agents in Medicinal Chemistry (2022) Vol. 22, Iss. 20, pp. 3370-3381
Closed Access | Times Cited: 20

Showing 20 citing articles:

The potential role of miRNAs in the pathogenesis of testicular germ cell tumors - A Focus on signaling pathways interplay
Ahmed S. Doghish, Hebatallah Ahmed Mohamed Moustafa, Mohammed S. Elballal, et al.
Pathology - Research and Practice (2023) Vol. 248, pp. 154611-154611
Closed Access | Times Cited: 30
Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review
Mostafa A. Mansour, Asmaa M. AboulMagd, Samar H. Abbas, et al.
RSC Advances (2023) Vol. 13, Iss. 27, pp. 18825-18853
Open Access | Times Cited: 24
Tetracycline antibiotics: Potential anticancer drugs
Jiayu Li, Yuan Qin, Chenhao Zhao, et al.
European Journal of Pharmacology (2023) Vol. 956, pp. 175949-175949
Closed Access | Times Cited: 16
Structural characterization and in silico evaluation of bioactive compounds from Rhus cotinus (Syn. Cotinus coggygria) roots as potential EGFR inhibitors for brain Cancer
Divya Gairola, A. J. Yusuf
Results in Chemistry (2025), pp. 102101-102101
Open Access
Semi-synthesis and biological activities of heterocyclic compounds containing camphor
Zeinab S. Hamza, Wael N. Hozzein, Khaled El‐Adl, et al.
RSC Advances (2025) Vol. 15, Iss. 17, pp. 13199-13213
Open Access
Cisplatin-based Liposomal Nanocarriers for Drug Delivery in Lung Cancer Therapy: Recent Progress and Future Outlooks
Kave Mohammad-Jafari, Seyed Morteza Naghib, M. R. Mozafari
Current Pharmaceutical Design (2024) Vol. 30, Iss. 36, pp. 2850-2881
Closed Access | Times Cited: 3
Immune‐related interaction perturbation networks unravel biological peculiars and clinical significance of glioblastoma
Zaoqu Liu, Yudi Xu, Wang Yu-hui, et al.
iMeta (2023) Vol. 2, Iss. 3
Open Access | Times Cited: 7
Advancements, challenges, and future frontiers in covalent inhibitors and covalent drugs: A review
Muhammad Salman Hameed, Hongxuan Cao, Li Guo, et al.
European Journal of Medicinal Chemistry Reports (2024), pp. 100217-100217
Open Access | Times Cited: 2
Design, formulation, biopharmaceutical evaluation and in-vitro screening of boldine phytosomes for breast cancer therapy
P. Padmakumari, Ram Mohan Manda
Materials Today Proceedings (2023)
Closed Access | Times Cited: 6
Phase I/IIa Trial in Advanced Pancreatic Ductal Adenocarcinoma Treated with Cytotoxic Drug-Packaged, EGFR-Targeted Nanocells and Glycolipid-Packaged Nanocells
Vinod Ganju, Gavin Marx, Scott Pattison, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 2, pp. 304-314
Closed Access | Times Cited: 4
Integrated PBPK-EO modeling of osimertinib to predict plasma concentrations and intracranial EGFR engagement in patients with brain metastases
Feng Liang, Yimei Zhang, Qian Xue, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Novel s-Triazine Derivatives as Potential Anticancer Agents: Synthesis, DFT, DNA Binding, Molecular Docking, MD Simulation and in silico ADMET Profiling
Alia Mushtaq, Muhammad Moazzam Naseer
Journal of Molecular Structure (2024) Vol. 1322, pp. 140558-140558
Closed Access | Times Cited: 1
Tumor-associated Macrophages Mediate Gefitinib Resistance in Lung Cancer through HGF/c-met Signaling Pathway
Xiali Tang, Yu Chen, Demin Jiao, et al.
Anti-Cancer Agents in Medicinal Chemistry (2023) Vol. 24, Iss. 1, pp. 30-38
Closed Access | Times Cited: 3
Therapeutic Potential and Pharmacognosy of Natural Biomolecules in the Treatment of Various Cancers: Strategy to Target Insight
Mohd Adnan
Anti-Cancer Agents in Medicinal Chemistry (2022) Vol. 22, Iss. 20, pp. 3324-3324
Closed Access | Times Cited: 4
Integrated PBPK-EO Modeling of Osimertinib: Predicting Pharmacokinetics, Intracranial EGFR Engagement, and Optimal Dosing Strategies in Clinical Settings
Feng Liang, Yimei Zhang, Qian Xue, et al.
Research Square (Research Square) (2024)
Open Access
The Sweet and Sour of Glycan Targeting in Cancer
Guillermina Rado, Santiago A. Rodríguez-Zraquia, Pablo Lores, et al.
Interdisciplinary cancer research (2024)
Closed Access
Identification of membrane proteins targeted by small-molecule compounds using nanomagnetic beads
Yasufumi Kikuchi, Takayuki Ando, Tadashi Ashizawa, et al.
Biomedical Research (2024) Vol. 45, Iss. 5, pp. 179-186
Open Access
Pancreatic Stromal Cell-derived Oncostatin M Confers Drug Resistance to a Multi-tyrosine Kinase Inhibitor in Pancreatic Cancer Cells
Daisuke Tatsuda, Junjiro Yoshida, Tomokazu Ohishi, et al.
Anticancer Research (2023) Vol. 43, Iss. 6, pp. 2477-2489
Open Access | Times Cited: 1
Significance of EGFR investigation in odontogenic keratocyst: a narrative review
Valentina Vasiljevic, Jasmina Obradović, Vladimir Jurišić
Molecular Biology Reports (2023) Vol. 50, Iss. 8, pp. 7089-7098
Closed Access | Times Cited: 1
P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure
Jing Wang, M. Merve Susam, Changpei Gan, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 9, pp. 1124-1124
Open Access
Page 1

Scroll to top